On Monday, Harmony Biosciences got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96.
The upgrade means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. Winning stocks often have a 95 or higher score in the early stages of a new price run, so that's an important benchmark to look for when looking for the best stocks to buy and watch.
Harmony Biosciences broke out earlier, but has fallen back below the prior 35.40 entry from a consolidation. In the scenario where a stock breaks out then falls 7% or more below the entry price, it's considered a failed breakout. If that happens, it's best to wait for a new pattern to take shape.
Looking For The Best Stocks To Buy And Watch? Start Here
The stock has a 95 EPS Rating, which means its recent quarterly and longer-term annual earnings growth tops 95% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
In Q4, the company reported 48% earnings growth. Sales growth increased 20%, up from 16% in the prior quarter. That marks one quarter of accelerating revenue growth.
Harmony Biosciences earns the No. 12 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Krystal Biotech and Catalyst Pharmaceuticals are among the top 5 highly-rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
